×

Do you want to link to this External Site and leave Amgen.com?

YOU ARE NOW LEAVING AMGEN'S WEB SITE. Amgen takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.

×

Do you want to link to this External Site and leave Amgen.com?

YOU ARE NOW LEAVING AMGEN'S WEB SITE. Amgen takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.

×

Do you want to link to this External Site and leave Amgen.com?

YOU ARE NOW LEAVING AMGEN'S WEB SITE. Amgen takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.

×

Do you want to link to this External Site and leave Amgen.com?

YOU ARE NOW LEAVING AMGEN'S WEB SITE. Amgen takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.

Amgen at ASCO 2013

Results from studies involving Amgen's oncology portfolio will be presented at the 2013 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place in Chicago May 31 – June 4, 2013.

Abstracts are available on the ASCO website at http://abstract.asco.org and updated data will be presented at the meeting.

If you are at ASCO, stop by Amgen's booth #7042 to learn more about Amgen Oncology.

Follow Amgen on Twitter at http://twitter.com/amgen to receive news updates during ASCO.


June 1, 2013

Press Release: Amgen Presents Positive Results From Talimogene Laherparepvec Phase 3 Study in Patients With Metastatic Melanoma

May 15, 2013

Press Release: Amgen Highlights Data To Be Presented at American Society of Clinical Oncology Annual Meeting

May 15, 2013

Press Release: New Analyses Identify Predictive Biomarkers for Vectibix® (Panitumumab) in Patients With Metastatic Colorectal Cancer